Papillomavirus and treatment

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 181-191

  Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Cervical carcinoma; Cidofovir; Papillomavirus; Vaccines; Warts

Indexed keywords

ACICLOVIR; ANTIGEN; BLEOMYCIN; CANDIDA ANTIGEN; CAPSID PROTEIN; CHLOROACETIC ACID; CIDOFOVIR; CIMETIDINE; DICHLOROACETIC ACID; FLUOROURACIL; FORMALDEHYDE; GLUTARALDEHYDE; HEAT SHOCK PROTEIN 65; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERFERON; MUMPS ANTIGEN; PHOTOSENSITIZING AGENT; PODOPHYLLIN; PODOPHYLLOTOXIN; PROTEIN E7; RETINOIC ACID; RIBAVIRIN; SALICYLIC ACID; SUCCINATE LITHIUM; TRICHLOROACETIC ACID; TRICHOPHYTON ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WART VIRUS VACCINE;

ACTINIC KERATOSIS; CANCER ADJUVANT THERAPY; CAUTERIZATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONDYLOMA; CONDYLOMA ACUMINATUM; CRYOSURGERY; CRYOTHERAPY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SCREENING; EPITHELIUM CELL; FEVER; FIBROMA; FREQUENCY ANALYSIS; HERPES; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOBIOLOGY; INFLAMMATION; INVASIVE CARCINOMA; LARYNX PAPILLOMATOSIS; LASER SURGERY; MOLLUSCUM CONTAGIOSUM; NECROSIS; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; SCIENCE; SHORT SURVEY; SYSTEMIC DISEASE; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA PLANTARIS; VERRUCA VULGARIS; WART VIRUS;

ANTIVIRAL AGENTS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYTOSINE; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES; WARTS;

DNA VIRUSES; HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 33747115336     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.06.007     Document Type: Short Survey

References (135)

1. Abdulkarim B., Sabri S., Deutsch E., Chagraoui H., Maggiorella L., Thierry J., Eschwege F., Vainchenker W., Chouaib S., and Bourhis J. Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21 (2002) 2334-2346
2. Alexander K.A. Diagnosis and management of human papillomavirus infections. Pediatr. Infect. Dis. J. 24 (2005) 1007-1008
3. Andrei G., Snoeck R., Piette J., Delvenne P., and De Clercq E. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol. Res. 10 (1998) 533-539
4. Andrei G., Snoeck R., Piette J., Delvenne P., and De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10 (1998) 523-531
5. Andrei G., Snoeck R., Schols D., and De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol. Res. 12 (2000) 397-408
6. Arican O., Guneri F., Bilgic K., and Karaoglu A. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J. Dermatol. 31 (2004) 627-631
7. Armbruster C., Kreuzer A., Vorbach H., Huber M., and Armbruster C. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur. Respir. J. 17 (2001) 830-831
8. Baker G.E., and Tyring S.K. Therapeutic approaches to papillomavirus infections. Dermatol. Clin. 15 (1997) 331-340
9. Baseman J.G., and Koutsky L.A. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32 Suppl. 1 (2005) S16-S24
10. Barret T.J., Silbar J.D., and McGinley J.P. Genital warts-a venereal disease. J. Amer. Med. Assoc. 154 (1954) 333-334
11. Bell M.C., Crowley-Nowick P., Bradlow H.L., Sepkovic D.W., Schmidt-Grimminger D., Howell P., Mayeaux E.J., Tucker A., Turbat-Herrera E.A., and Mathis J.M. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol. Oncol. 78 (2000) 123-129
12. Bernard H.U. Phylogeny and taxonomy of papillomaviruses. In: Campo M.S. (Ed). Papillomavirus Research: From Natural History to Vaccines and Beyond (2006), Caister Academic Press, Norfolk 11-17
13. Bernard H.U. Coevolution of papillomaviruses with human populations. Trends Microbiol. 2 (1994) 140-143
14. Bernard H.U., Chan S.Y., and Delius H. Evolution of papillomaviruses. Curr. Top. Microbiol. Immunol. 186 (1994) 33-54
15. Bernard H.U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J. Clin. Virol. 32 Suppl. 1 (2005) S1-S6
16. Bigrigg A., Haffenden D.K., Sheehan A.L., Codling B.W., and Read M.D. Efficacy and safety of large-loop excision of the transformation zone. Lancet 343 (1994) 32-34
17. Blanpain C., Lowry W.E., Geoghegan A., Polak L., and Fuchs E. Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 118 (2004) 635-648
18. Bleeker M.C., Hogewoning C.J., Voorhorst F.J., van den Brule A.J., Snijders P.J., Starink T.M., Berkhof J., and Meijer C.J. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int. J. Cancer 107 (2003) 804-810
19. Bosch F.X., de Sanjosé S., Castellsagué X., Moreno V., and Muñoz N. Epidemiology of human papillomavirus infections and associations with cervical cancer: new opportunities for prevention. In: Campo M.S. (Ed). Papillomavirus Research: From Natural History to Vaccines and Beyond (2006), Caister Academic Press, Norfolk 19-39
20. Bonnez W. Immunization against genital human papillomaviruses. Pediatr. Infect. Dis. J. 24 (2005) 1005-1006
21. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J.T., and Lowy D.R. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69 (1995) 3959-3963
22. Burk R.D., Ho G.Y., Beardsley L., Lempa M., Peters M., and Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J. Infect. Dis. 174 (1996) 679-689
23. Carter J.J., Wipf G.C., Hagensee M.E., McKnight B., Habel L.A., Lee S.K., Kuypers J., Kiviat N., Daling J.R., and Koutsky L.A. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J. Infect. Dis. 172 (1995) 11-18
24. Castellsague X., Bosch F.X., and Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Res. 89 (2002) 191-199
25. Chen L., Mizuno M.T., Singhal M.C., Hu S.L., Galloway D.A., Hellstrom I., and Hellstrom K.E. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J. Immunol. 148 (1992) 2617-2621
26. Clawson G.A., Miranda G.Q., Sivarajah A., Xin P., Pan W., Thiboutot D., and Christensen N.D. Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA. Gene Ther. 11 (2004) 1331-1341
27. Chow L.T., and Broker T.R. Mechanisms and regulation of papillomavirus DNA replication. In: Campo M.S. (Ed). Papillomavirus Research: From Natural History to Vaccines and Beyond (2006), Caister Academic Press, Norfolk 53-71
28. Ciuffo G. Innesto positive con filtrato di verruca vulgare. Giorn. Ital. Mal. Venereol. 48 (1907) 12-17
29. Christensen N.D., Hopfl R., DiAngelo S.L., Cladel N.M., Patrick S.D., Welsh P.A., Budgeon L.R., Reed C.A., and Kreider J.W. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J. Gen. Virol. 75 Pt 9 (1994) 2271-2276
30. Christensen N.D., Kirnbauer R., Schiller J.T., Ghim S.J., Schlegel R., Jenson A.B., and Kreider J.W. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205 (1994) 329-335
31. Christensen N.D., Pickel M.D., Budgeon L.R., and Kreider J.W. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res. 48 (2000) 131-142
32. Coremans G., Margaritis V., Snoeck R., Wyndaele J., De Clercq E., and Geboes K. Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata. Dis. Colon Rectum 46 (2003) 1103-1108
33. Dancey D.R., Chamberlain D.W., Krajden M., Palefsky J., Alberti P.W., and Downey G.P. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature. Chest 118 (2000) 1210-1214
34. de Bilderling G., Bodart E., Lawson G., Tuerlinckx D., Remacle M., Naesens L., De Clercq E., and Snoeck R. Successful use of intralesional and intravenous cidofovir in association with indole-3-carbinol in an 8-year-old girl with pulmonary papillomatosis. J. Med. Virol. 75 (2005) 332-335
35. De Clercq E., Andrei G., Balzarini J., Hatse S., Liekens S., Naesens L., Neyts J., and Snoeck R. Antitumor potential of acyclic nucleoside phosphonates. Nucleosides Nucleotides 18 (1999) 759-771
36. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16 (2003) 569-596
37. De Clercq E., and Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 4 (2005) 928-940
38. de Sanjose S., Munoz N., Bosch F.X., Reimann K., Pedersen N.S., Orfila J., Ascunce N., Gonzalez L.C., Tafur L., and Gili M. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int. J. Cancer 56 (1994) 358-363
39. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur H.H. Classification of papillomaviruses. Virology 324 (2004) 17-27
40. Derkay C.S., Smith R.J., McClay J., van Burik J.A., Wiatrak B.J., Arnold J., Berger B., and Neefe J.R. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann. Otol. Rhinol. Laryngol. 114 (2005) 730-737
41. DiPaolo J.A., and Alvarez-Salas L.M. Advances in the development of therapeutic nucleic acids against cervical cancer. Expert. Opin. Biol. Ther. 4 (2004) 1251-1264
42. Doorbar J. The papillomavirus life cycle. J. Clin. Virol. 32 Suppl. 1 (2005) S7-S15
43. Duringer C., Hamiche A., Gustafsson L., Kimura H., and Svanborg C. HAMLET interacts with histones and chromatin in tumor cell nuclei. J. Biol. Chem. 278 (2003) 42131-42135
44. Egawa K. Do human papillomaviruses target epidermal stem cells?. Dermatology 207 (2003) 251-254
45. Eisemann C., Fisher S.G., Gross G., Muller M., and Gissmann L. Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups. J. Gen. Virol. 77 Pt 8 (1996) 1799-1803
46. Edwards L., Ferenczy A., Eron L., Baker D., Owens M.L., Fox T.L., Hougham A.J., and Schmitt K.A. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch. Dermatol. 134 (1998) 25-30
47. Evans T.G., Bonnez W., Rose R.C., Koenig S., Demeter L., Suzich J.A., O'Brien D., Campbell M., White W.I., Balsley J., and Reichman R.C. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183 (2001) 1485-1493
48. Fehrmann F., and Laimins L.A. Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22 (2003) 5201-5207
49. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., ter Schegget J., Melief C.J., and Kast W.M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23 (1993) 2242-2249
50. Focht III D.R., Spicer C., and Fairchok M.P. The efficacy of duct tape vs cryotherapy in the treatment of verruca vulgaris (the common wart). Arch. Pediatr. Adolesc. Med. 156 (2002) 971-974
51. Fox P.A., and Tung M.Y. Human papillomavirus: burden of illness and treatment cost considerations. Am. J. Clin. Dermatol. 6 (2005) 365-381
52. Fox P.A. Human papillomavirus and anal intraepithelial neoplasia. Curr. Opin. Infect. Dis. 19 (2006) 62-66
53. Frazer I.H., Cox J.T., Mayeux Jr. E.J., Franco E.L., Moscicki A.B., Palekfsky J.M., Ferris D.G., Ferenczy A.S., and Villa L.L. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr. Infect. Dis. J. 25 Suppl. 2 (2006) S65-S81 quiz S82
54. Johnson J.A., and Gangemi J.D. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-1[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob. Agents Chemother. 43 (1999) 1198-1205
55. Gerein V., Rastorguev E., Gerein J., Draf W., and Schirren J. Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience. Otolaryngol. Head Neck Surg. 132 (2005) 392-394
56. Giles M., and Garland S.M. HPV vaccines. In: Campo M.S. (Ed). Papillomavirus Research: From Natural History to Vaccines and Beyond (2006), Caister Academic Press, Norfolk 341-356
57. Goldstone S.E., Palefsky J.M., Winnett M.T., and Neefe J.R. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum 45 (2002) 502-507
58. Gollnick H., Barasso R., Jappe U., Ward K., Eul A., Carey-Yard M., and Milde K. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int. J. STD AIDS 12 (2001) 22-28
59. Goodwin E.C., Yang E., Lee C.J., Lee H.W., DiMaio D., and Hwang E.S. Rapid induction of senescence in human cervical carcinoma cells. Proc. Natl. Acad. Sci. U.S.A 97 (2000) 10978-10983
60. Goodwin E.C., and DiMaio D. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc. Natl. Acad. Sci. U.S.A 97 (2000) 12513-12518
61. Govan V.A. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann. N.Y. Acad. Sci. 1056 (2005) 328-343
62. Gustafsson L., Leijonhufvud I., Aronsson A., Mossberg A.K., and Svanborg C. Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid. N. Engl. J. Med. 350 (2004) 2663-2672
63. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-Martins C.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., and Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
64. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., Mast T.C., Robinson R., Murphy B.R., Karron R.A., Dillner J., Schiller J.T., and Lowy D.R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93 (2001) 284-292
65. Hengge U.R., and Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm. Infect. 76 (2000) 143
66. Hogewoning C.J., Bleeker M.C., van den Brule A.J., Voorhorst F.J., Snijders P.J., Berkhof J., Westenend P.J., and Meijer C.J. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int. J. Cancer 107 (2003) 811-816
67. Horn T.D., Johnson S.M., Helm R.M., and Roberson P.K. Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: a single-blinded, randomized, and controlled trial. Arch. Dermatol. 141 (2005) 589-594
68. Howley P.M., and Lowy D.R. Papillomaviruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia 2197-2229
69. International Agency for Research on Cancer, 1995. Human papillomaviruses. In: IARC (Ed.), IARC monographs on the evaluation of carcinogenic risks to humans, vol. 64.
70. Jennings M.B., Ricketti J., Guadara J., Nach W., and Goodwin S. Treatment for simple plantar verrucae: monochloroacetic acid and 10% formaldehyde versus 10% formaldehyde alone. J. Am. Pediatr. Med. Assoc. 96 (2006) 53-58
71. Kenneth A.A. Diagnosis and management of human papillomavirus infections. Pediatric Infec. Dis. J. 24 (2005) 1007-1008
72. Kimberlin D.W. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res. 63 (2004) 141-151
73. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A 89 (1992) 12180-12184
74. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., McGarvie G.M., Schiller J.T., Lowy D.R., and Campo M.S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219 (1996) 37-44
75. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., Chiacchierini L.M., and Jansen K.U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (2002) 1645-1651
76. Lacey C.J. Therapy for genital human papillomavirus-related disease. J. Clin. Virol. 32 Suppl. 1 (2005) S82-S90
77. Lee A.S., and Rosen C.A. Efficacy of cidofovir injection for the treatment of recurrent respiratory papillomatosis. J. Voice 18 (2004) 551-556
78. Lunec A. Issues raised by prophylactic vaccine for cervical cancer. Lancet Oncol. 6 (2005) 923-924
79. Mandell D.L., Arjmand E.M., Kay D.J., Casselbrant M.L., and Rosen C.A. Intralesional cidofovir for pediatric recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 130 (2004) 1319-1323
80. Manhart L.E., and Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm. Dis. 29 (2002) 725-735
81. Martin-Hirsch P.L., Whitehurst C., Buckley C.H., Moore J.V., and Kitchener H.C. Photodynamic treatment for lower genital tract intraepithelial neoplasia. Lancet 351 (1998) 1403
82. Martin-Hirsch P., Kitchener H.C., and Hampson I.N. Photodynamic therapy of lower genital tract neoplasia. Gynecol. Oncol. 84 (2002) 187-189
83. NIH Consensus Development Panel, 1996. National Institute Health Consensus Development Conference Statement: Cervical Cancer, April 1-3. J. Natl. Cancer Inst. Monographs 21, pp. vii-xiii.
84. Niu X.Y., Peng Z.L., Duan W.Q., Wang H., and Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int. J. Gynecol. Cancer 16 (2006) 743-751
85. Ohyama M., Terunuma A., Tock C.L., Radonovich M.F., Pise-Masison C.A., Hopping S.B., Brady J.N., Udey M.C., and Vogel J.C. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J. Clin. Invest. 116 (2006) 249-260
86. Ooi T., Barnetson R.S., Zhuang L., McKane S., Lee J.H., Slade H.B., and Halliday G.M. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br. J. Dermatol. 154 (2006) 72-78
87. Pasquale K., Wiatrak B., Woolley A., and Lewis L. Microdebrider versus CO2 laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope 113 (2003) 139-143
88. Peyton S.W., and Wiatrak B. Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children?. Int. J. Pediatr. Otorhinolaryngol. 68 (2004) 413-418
89. Rogan E.G. The natural chemopreventive compound indole-3-carbinol: state of the science. In Vivo 20 (2006) 221-228
90. Rohan T., Mann V., McLaughlin J., Harnish D.G., Yu H., Smith D., Davis R., Shier R.M., and Rawls W. PCR-detected genital papillomavirus infection: prevalence and association with risk factors for cervical cancer. Int. J. Cancer 49 (1991) 856-860
91. Rose R.C., Bonnez W., Reichman R.C., and Garcea R.L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J. Virol. 67 (1993) 1936-1944
92. Rosen C.A., and Bryson P.C. Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. J. Voice 18 (2004) 248-253
93. Scheurer M.E., Tortolero-Luna G., and Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int. J. Gynecol. Cancer 15 (2005) 727-746
94. Shehab N., Sweet B.V., and Hogikyan N.D. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy 25 (2005) 977-989
95. Shikowitz M.J., Abramson A.L., Steinberg B.M., DeVoti J., Bonagura V.R., Mullooly V., Nouri M., Ronn A.M., Inglis A., McClay J., and Freeman K. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 131 (2005) 99-105
96. Silverman D.A., and Pitman M.J. Current diagnostic and management trends for recurrent respiratory papillomatosis. Curr. Opin. Otolaryngol. Head Neck Surg. 12 (2004) 532-537
97. Snoeck R., Van Ranst M., Andrei G., De Clercq E., De Wit S., Poncin M., and Clumeck N. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N. Engl. J. Med. 333 (1995) 943-944
98. Snoeck R., Andrei G., and De Clercq E. Specific therapies for human papilloma virus infections. Curr. Opin. Infec. Dis. 11 (1998) 733-737
99. Snoeck R., Wellens W., Desloovere C., Van Ranst M., Naesens L., De Clercq E., and Feenstra L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J. Med. Virol. 54 (1998) 219-225
100. Snoeck R., Noel J.C., Muller C., De Clercq E., and Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol. 60 (2000) 205-209
101. Snoeck R., Andrei G., and De Clercq E. Cidofovir in the treatment of HPV-associated lesions. Verh. K. Acad. Geneeskd. Belg. 63 (2001) 93-120 (discussion)
102. Snoeck R., Van Laethem Y., De Clercq E., De Maubeuge J., and Clumeck N. Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. Arch. Intern. Med. 161 (2001) 2382-2384
103. Snoeck R., Bossens M., Parent D., Delaere B., Degreef H., Van Ranst M., Noel J.C., Wulfsohn M.S., Rooney J.F., Jaffe H.S., and De Clercq E. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin. Infect. Dis. 33 (2001) 597-602
104. Snoeck R., and De Clercq E. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr. Opin. Investig. Drugs 3 (2002) 1561-1566
105. Spitzer M., Apgar B.S., and Brotzman G.L. Management of histologic abnormalities of the cervix. Am. Fam. Physician 73 (2006) 105-112
106. Stanley M. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res. 89 (2002) 241-248
107. Stanley M. The end for genital human papillomavirus infections?. Lancet Oncol. 6 (2005) 256-257
108. Stanley M.A. Immunobiology of papillomaviruses. In: Campo M.S. (Ed). Papillomavirus Research: From Natural History to Vaccines and Beyond (2006), Caister Academic Press, Norfolk 311-319
109. Stern P.L. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J. Clin. Virol. 32 Suppl. 1 (2005) S72-S81
110. Stone K.M., Karem K.L., Sternberg M.R., McQuillan G.M., Poon A.D., Unger E.R., and Reeves W.C. Seroprevalence of human papillomavirus type 16 infection in the United States. J. Infect. Dis. 186 (2002) 1396-1402
111. Strauss M.J., Shaw E.W., Bunting H., and Melnick J.L. "Crystalline" virus-like particles from skin papillomas characterized by intranuclear inclusion bodies. Proc. Soc. Exptl. Med. 72 (1949) 46-50
112. Sundberg J.P., Van Ranst M., Burk R.D., and Jenson A.B. The nonhuman (animal) papillomaviruses: host range, epitope conservation, and molecular diversity. In: Gross G., and von Krogh G. (Eds). Human Papillomavirus Infections in Dermatovenereology (1997), CRC Press, Boca Raton
113. Sundberg J.P., Van Ranst M., Montali R., Homer B.L., Miller W.H., Rowland P.H., Scott D.W., England J.J., Dunstan R.W., Mikaelian I., and Jenson A.B. Feline papillomas and papillomaviruses. Vet. Pathol. 37 (2000) 1-10
114. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., and Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U.S.A 92 (1995) 11553-11557
115. Svensson C., Agerstam H., Aronson A., Bjerkvig R., Duringer C., Fischer W., Gustafsson L., Hallgren O., Leijonhuvud I., Linse S., Mossberg A.K., Nilsson H., Pettersson J., and Svensson M. HAMLET kills tumor cells by an apoptosis-like mechanism-cellular, molecular, and therapeutic aspects. Adv. Cancer Res. 88 (2003) 1-29
116. Szeps M., Dahlgren L., Aaltonen L.M., Ohd J., Kanter-Lewenshon L., Dahlstrand H., Munck-Wikland E., Grander D., and Dalianis T. Human papillomavirus, viral load and proliferation rate in recurrent respiratory papillomatosis in response to alpha interferon treatment. J. Gen. Virol. 86 (2005) 1695-1702
117. Tachezy R., Rector A., Havelkova M., Wollants E., Fiten P., Opdenakker G., Jenson B., Sundberg J., and Van Ranst M. Avian papillomaviruses: the parrot Psittacus erithacus papillomavirus (PePV) genome has a unique organization of the early protein region and is phylogenetically related to the chaffinch papillomavirus. BMC Microbiol. 2 (2002) 19
118. Tang S., Tao M., McCoy Jr. J.P., and Zheng Z.M. Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene 25 (2006) 2094-2104
119. Toro J.R., Sanchez S., Turiansky G., and Blauvelt A. Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox. Dermatol. Clin. 21 (2003) 301-309
120. Trottier H., and Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine (2005) (only available online)
121. Vambutas A., and Steinberg B.M. Recurrent respiratory papillomatosis, HPV, and impact on host response. In: Campo M.S. (Ed). Papillomavirus Research: From Natural History to Vaccines and Beyond (2006), Caister Academic Press, Norfolk 255-267
122. Van Cutsem E., Snoeck R., Van Ranst M., Fiten P., Opdenakker G., Geboes K., Janssens J., Rutgeerts P., Vantrappen G., and De Clercq E. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Med. Virol. 45 (1995) 230-235
123. Van Valkenborgh I., Wellens W., De Boeck K., Snoeck R., De Clercq E., and Feenstra L. Systemic cidofovir in papillomatosis. Clin. Infect. Dis. 32 (2001) E62-E64
124. Vandepapeliere P., Barrasso R., Meijer C.J., Walboomers J.M., Wettendorff M., Stanberry L.R., and Lacey C.J. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J. Infect. Dis. 192 (2005) 2099-2107
125. Venturini F., Braspenning J., Homann M., Gissmann L., and Sczakiel G. Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: anti-proliferative effects on HPV 16-transformed cells. Nucleic Acids Res. 27 (1999) 1585-1592
126. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., Wheeler C.M., Koutsky L.A., Malm C., Lehtinen M., Skjeldestad F.E., Olsson S.E., Steinwall M., Brown D.R., Kurman R.J., Ronnett B.M., Stoler M.H., Ferenczy A., Harper D.M., Tamms G.M., Yu J., Lupinacci L., Railkar R., Taddeo F.J., Jansen K.U., Esser M.T., Sings H.L., Saah A.J., and Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
127. von Krogh G., and Longstaff E. Podophyllin office therapy against condyloma should be abandoned. Sex Transm. Infect. 77 (2001) 409-412
128. Wang S.S., Schiffman M., Shields T.S., Herrero R., Hildesheim A., Bratti M.C., Sherman M.E., Rodriguez A.C., Castle P.E., Morales J., Alfaro M., Wright T., Chen S., Clayman B., Burk R.D., and Viscidi R.P. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br. J. Cancer 89 (2003) 1248-1254
129. Wells S.I., Francis D.A., Karpova A.Y., Dowhanick J.J., Benson J.D., and Howley P.M. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21(CIP)-dependent pathways. EMBO J. 19 (2000) 5762-5771
130. Wemer R.D., Lee J.H., Hoffman H.T., Robinson R.A., and Smith R.J. Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 114 (2005) 836-839
131. White W.I., Wilson S.D., Bonnez W., Rose R.C., Koenig S., and Suzich J.A. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J. Virol. 72 (1998) 959-964
132. Yuan F., Chen D.Z., Liu K., Sepkovic D.W., Bradlow H.L., and Auborn K. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res. 19 (1999) 1673-1680
133. Zabawski Jr. E.J., Sands B., Goetz D., Naylor M., and Cockerell C.J. Treatment of verruca vulgaris with topical cidofovir. JAMA 278 (1997) 1236
134. Zabawski Jr. E.J., and Cockerell C.J. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J. Am. Acad. Dermatol. 39 (1998) 741-745
135. Zhang B., Chen W., and Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc. Natl. Acad. Sci. U.S.A 103 (2006) 437-442